Cargando…

Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review

Background: The introduction of tyrosine kinase inhibitor (TKI) therapy has dramatically improved the clinical effectiveness of patients with locally advanced and/or metastatic gastrointestinal stromal tumors (GIST), and this systematic review was conducted aiming at the cost-effectiveness analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Mingyang, Yang, Yang, Liao, Weiting, Li, Qiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784780/ https://www.ncbi.nlm.nih.gov/pubmed/35083189 http://dx.doi.org/10.3389/fpubh.2021.768765

Ejemplares similares

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
por: Liao, Weiting, et al.
Publicado: (2021)

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors
por: Tomasetti, Cristian, et al.
Publicado: (2013)

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors
por: Li, Jian, et al.
Publicado: (2018)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
por: Feng, Mingyang, et al.
Publicado: (2022)

Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy
por: Qiu, Hai-Bo, et al.
Publicado: (2018)

Downsizing Treatment with Tyrosine Kinase Inhibitors in Patients with Advanced Gastrointestinal Stromal Tumors Improved Resectability
por: Sjölund, Katarina, et al.
Publicado: (2010)

Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

The Role of Surgical Resection Following Tyrosine Kinase Inhibitors Treatment in Patients with Advanced Gastrointestinal Stromal Tumors: A Systematic Review and Meta-analysis
por: Guo, Yinghao, et al.
Publicado: (2019)

Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors
por: Wang, Feng, et al.
Publicado: (2021)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors
por: Na, Young-Soon, et al.
Publicado: (2017)

Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature
por: van de Wal, Deborah, et al.
Publicado: (2022)

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance
por: Boichuk, Sergei, et al.
Publicado: (2017)

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors
por: Obata, Y, et al.
Publicado: (2017)

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
por: Mahadevan, Daruka, et al.
Publicado: (2014)

Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors
por: Sardinha, Ruth, et al.
Publicado: (2013)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Neoadjuvant tyrosine kinase inhibitors in rectal gastrointestinal stromal tumours: a provision for enhanced oncological and functional outcomes
por: Yong, Zachary Zihui, et al.
Publicado: (2021)

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)
por: Le Tourneau, Christophe, et al.
Publicado: (2007)

Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review
por: Zhang, Yefan, et al.
Publicado: (2023)

Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
por: Qiu, Tingting, et al.
Publicado: (2021)

Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials
por: Wu, Lile, et al.
Publicado: (2014)

Long-term progression-free survival achieved in the skull base metastasis of gastrointestinal stromal tumor with introduction of tyrosine kinase inhibitor: illustrative case
por: Kawanishi, Akiya, et al.
Publicado: (2022)

Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

PB1771: OVERCOMING RESISTANCE TO TYROSINE KINASE INHIBITORS IN MYELOID LEUKEMIA CELLS THROUGH ENHANCED FERROPTOSIS
por: Chien, Chih-Fang Chang, et al.
Publicado: (2023)

PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review
por: Lin, Cuiping, et al.
Publicado: (2022)

Cost-effectiveness analysis of myopia management: A systematic review
por: Agyekum, Sylvia, et al.
Publicado: (2023)

Financial costs of pediatric cancer management in Africa: systematic review
por: Mjumbe, Criss Koba, et al.
Publicado: (2023)

Combination of Type I and II tyrosine kinase inhibitors—avapritinib and sunitinib—in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report
por: Guo, Xiaodan, et al.
Publicado: (2022)

Raf kinase inhibitor protein combined with phosphorylated extracellular signal-regulated kinase offers valuable prognosis in gastrointestinal stromal tumor
por: Qu, Wen-Zhi, et al.
Publicado: (2023)

The cost-effectiveness of digital health interventions: A systematic review of the literature
por: Gentili, Andrea, et al.
Publicado: (2022)

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
por: Yang, Yang, et al.
Publicado: (2022)

Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
por: Lee, Ji Hyun, et al.
Publicado: (2022)

Comprehensive league table of cost-utility ratios: A systematic review of cost-effectiveness evidence for health policy decisions in India
por: Shah, Komal, et al.
Publicado: (2022)

Cost-Effectiveness of Pre-exposure Prophylaxis Among Men Who Have Sex With Men in China: A Systematic Review
por: Mi, Yuanqi, et al.
Publicado: (2022)

Epidemiology, survival, and costs of localized gastrointestinal stromal tumors
por: Rubin, Jaime L, et al.
Publicado: (2011)

PB1935: CARDIOTOXICITY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITORS: A REVIEW OF REAL-WORLD OBSERVATIONAL EVIDENCE
por: Balijepalli, Chakrapani, et al.
Publicado: (2023)

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
por: Hill, Andrew, et al.
Publicado: (2016)

Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors
por: Van Looy, Thomas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0l3kkb24dpkjqhsmtrvmb2r20e